During the past decade, Herzzentrum Saar conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Herzzentrum Saar" #1 collaborator was "Daiichi Sankyo Deutschland GmbH" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Herzzentrum Saar" are "Hypercholesterolemia" (1 trials), "Mixed Dyslipidemia" (1 trials) and "Non-valvular Atrial Fibrillation" (1 trials). Many other conditions were trialed in "Herzzentrum Saar" in a lesser frequency.

Most popular intervention types in "Herzzentrum Saar" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Bempedoic acid and/or its fixed-dose combination with ezetimibe" (1 trials) and "Edoxaban" (1 trials). Other intervention names were less common.

The vast majority of trials in "Herzzentrum Saar" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Herzzentrum Saar". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Herzzentrum Saar, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Herzzentrum Saar, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".